Shopping Cart
- Remove All
- Your shopping cart is currently empty
SC 51089 is a selective prostaglandin receptor PGE2 antagonist with selectivity for prostaglandin receptor subtypes and antinociceptive activity that improves motor deficits and rescues memory decline in the Huntington's disease R6/1 mouse model .
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $293 | 6-8 weeks | |
5 mg | $722 | 6-8 weeks | |
10 mg | $987 | 6-8 weeks | |
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | SC 51089 is a selective prostaglandin receptor PGE2 antagonist with selectivity for prostaglandin receptor subtypes and antinociceptive activity that improves motor deficits and rescues memory decline in the Huntington's disease R6/1 mouse model . |
Targets&IC50 | FP:61.1 μM (Ki), EP1:1.3 μM (Ki), 11.2 μM (Ki):EP3, TP:11.2 μM (Ki) |
In vivo | In the R6/1 mouse model of Huntington's disease (HD), treatment with SC 51089 (40 μg/kg/day; i.p.) for 28 days improved motor coordination and balance deficits, rescued long-term memory loss, as well as improved the expression of specific synaptic markers and reduced the number of intranuclear inclusions of huntingtin protein in the striatum and hippocampus[3]. |
Alias | SC 51089 free base |
Molecular Weight | 459.33 |
Formula | C22H20Cl2N4O3 |
Cas No. | 146033-02-5 |
Relative Density. | no data available |
Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (189.19 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.